Organism: Homo sapiens
Gene: 39324_at
Selected probe(set): 213469_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39324_at (213469_at) across 6674 perturbations tested by GENEVESTIGATOR:

Relative Expression (log2-ratio):-4.459337
Number of Samples:4 / 4

Experimental	B-CLL study 11 (DMSO)
	Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control	vehicle (DMSO) treated normal B-cell sample
	MACS purified resting B-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

Relative Expression (log2-ratio):4.072481
Number of Samples:3 / 15

Experimental	methyl methanesulfonate study 6 (320µM)
	TK6 cells treated with 320µM methyl methanesulfonate for 24h. ATC code:---
Control	untreated TK6 cell sample
	Untreated TK6 cell line. Cells where left untreated for 24h before harvesting.

Relative Expression (log2-ratio):4.037176
Number of Samples:3 / 4

Experimental	lung cancer study 1 (PDX; basaloid carcinoma; primary)
	Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary basaloid carcinoma of the lung (subcutaneously implanted).
Control	lung cancer study 1 (PDX; adenosquamous carcinoma; primary)
	Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenosquamous carcinoma of the lung (subcutaneously implanted).

Relative Expression (log2-ratio):-3.9047918
Number of Samples:4 / 4

Experimental	B-CLL study 11 (rolipram)
	Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control	rolipram study 4 (normal B-cell; 20uM)
	MACS purified resting B-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

Relative Expression (log2-ratio):3.7727852
Number of Samples:2 / 2

Experimental	ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary)
	Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary transitional cell carcinoma, NOS of the ovary (subcutaneously implanted).
Control	ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)
	Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the ovary (subcutaneously implanted).

Relative Expression (log2-ratio):3.6898785
Number of Samples:3 / 22

Experimental	lung cancer study 1 (PDX; basaloid carcinoma; primary)
	Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary basaloid carcinoma of the lung (subcutaneously implanted).
Control	lung cancer study 1 (PDX; adenocarcinoma, NOS; primary)
	Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the lung (subcutaneously implanted).

Relative Expression (log2-ratio):-3.6894846
Number of Samples:4 / 4

Experimental	B-CLL study 11 (DMSO)
	Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control	vehicle (DMSO) treated normal T-cell sample
	MACS purified T-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

Relative Expression (log2-ratio):-3.2905493
Number of Samples:2 / 3

Experimental	lung cancer study 1 (PDX; non-small cell carcinoma; primary)
	Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary non-small cell carcinoma of the lung (subcutaneously implanted).
Control	lung cancer study 1 (PDX; basaloid carcinoma; primary)
	Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary basaloid carcinoma of the lung (subcutaneously implanted).

Relative Expression (log2-ratio):3.2849607
Number of Samples:2 / 2

Experimental	T-helper activation study 1 (280min)
	Alloantigen specific helper T-cells were stimulated for 280min with anti-CD3/anti-CD28/IL-2 (100U/ml). T-helper cells were sorted as CD4+ CD25- cells from peripheral blood of healthy donors.
Control	unstimulated helper T-cell sample
	Unstimulated alloantigen specific helper T-cell sample derived from sorted CD4+ CD25- cells from peripheral blood of healthy donors.

Relative Expression (log2-ratio):3.2460842
Number of Samples:8 / 8

Experimental	PMA; ionomycine study 2
	CD4+ memory T cells derived from peripheral blood of healthy subjects were stimulated for 3 hours with phorbol 12-myristate 13-acetate (PMA, 10 ng/ml) and ionomycin (1 µg/ml). ATC code:---
Control	unstimulated CD4 memory T-cell sample
	Unstimulated CD4+ memory T cells derived from peripheral blood of healthy subjects.